François Verdier received his Pharm.D in Lyon in 1986 and his Ph.D in Immunotoxicology in Paris in 1993. He started his career in Toxicology with a Contract Research Organization (MDS) from 1988 to 1998, holding various functions including department manager, study director and business development manager. In 1998, he joined Aventis Pasteur, now Sanofi Pasteur, as head of non-clinical safety and pharmacodynamics, leading the non-clinical safety investigations and strategy for R&D projects and marketed products. François then moved to Regulatory Affairs as head of the French department and then global head of Regulatory Development. During this period being based in Europe and then in North America, he successfully registered several vaccines including pandemic flu or combo pediatric vaccines. Since 2013, he has dedicated most of his time to the global simultaneous submissions and registrations of the first vaccine against Dengue. This global program has been successful due to numerous interactions with Asian, North and Latin American authorities. His future challenges are the development of Zika and Malaria vaccines. Developing prophylactic drugs for unmet medical needs is really what motivates François. He strongly believes in innovative strategies to accelerate the development of such products. “Interacting very upfront with Regulatory Agencies and encouraging interactions based on trust and science definitively contribute to successful regulatory procedures”